

Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage

NCT07026994

Status	RECRUITING
Phase	Phase 2
Sponsor	Huashan Hospital
Enrollment	80 participants

Key Eligibility Criteria

Inclusion (6)

- Age ≥ 55 years;
- Diagnosed with "probable CAA with supporting pathology" or "probable CAA" according to the modified Boston criteria (version 1.5);
- High risk of recurrent ICH, defined as: 1 prior symptomatic ICH and presence of cortical superficial siderosis (cSS), or ≥ 2 prior symptomatic ICHs;
- Time interval since symptom onset of the most recent ICH: ≤ 3 months (earlier enrollment is preferred if criteria are met);
- Modified Rankin Scale (mRS) score ≤ 4 at randomization;
- ... and 1 more (see full listing online)

Exclusion (11)

- Secondary causes of ICH;
- Pre-existing moderate-to-severe renal, liver or blood disorders (anaemia [hemoglobin $< 10\text{g/dL}$], thrombocytopenia [platelet count $< 100 \times 10^9/\text{L}$], leucopenia [white blood cell $< 3 \times 10^9/\text{L}$], cirrhosis or severe hepatic dysfunction, renal insufficiency [estimated glomerular filtration rate (eGFR) $< 15\text{mL/min}$]);
- Prior diagnosis of gout, peripheral neuropathy, myopathy, inflammatory bowel disease or chronic diarrhea;
- Concurrent treatment with regular immune-suppressant (corticosteroids, cyclophosphamide, azathioprine, mycophenolate mofetil, rituximab), moderate-to-strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir) or P-glycoprotein inhibitors (cyclosporine, ranolazine);
- Known allergy, sensitivity or intolerance to colchicine;
- ... and 6 more (see full listing online)

Locations (3 total)

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
West China Hospital, Sichuan University, Chengdu, China
Huashan Hospital, Fudan University, Shanghai, China

<https://clinicaltrials.gov/study/NCT07026994>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.